Jeuveau® is a prescription medicine that is injected into muscles and used in adults for a short period of time (temporary) to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).
Jeuveau injections are performed in office and are very quick.
With Jeuveau, some patients have reported results as early as 2 days post injection. Most of the time, full results are seen a week post injection.
A Jeuveau treatment is priced based on the number of units needed. This varies from patient to patient. Jeuveau is priced at $14 per unit. On average, patients typically receive 30 to 40 units per visit for full correction
After Jeuveau injections, patients will temporarily have injection site swelling, or "bee stings," that subside very quickly. As with any injection based treatment, bruising is very common. Premier providers recommend patients to plan injectable appointments accordingly, allowing time for bruises to heal if needed.
Jeuveau® is an injectable treatment that stops your nerves from telling your facial muscles to flex, temporarily smoothing moderate to severe lines between the brows.
Premier providers recommend receiving Jeuveau injections every 90 days for optimal results.
Learn how you can save $40 on every Jeuveau treatment with free, easy Rewards.
READY TO SCHEDULE?
Book your medical or cosmetic appointment online. Complimentary consultations are available for cosmetic services.
What exactly is Jeuveau?
You know those pesky little wrinkles between your eyebrows that won’t go away? Well, they’re called glabellar lines, or “frown lines.” Jeuveau® is an injectable treatment that works to temporarily improve the appearance of moderate to severe frown lines in adults.
How does Jeuveau work?
When injected, Jeuveau® temporarily prevents your nerves from telling your facial muscles to flex. The result? In clinical trials, Jeuveau® was shown to temporarily improve the appearance of moderate to severe frown lines.
What are the results with Jeuveau?
In clinical trials, Jeuveau® was shown to temporarily improve the appearance of moderate to severe frown lines. In US studies, 68% and 70% of Jeuveau® patients had a 2-grade or better physician and patient-rated improvement in frown lines at Day 30. But that's not all. In a study conducted in Europe and Canada, 54% of patients had visible results as early as 2 days after treatment.* And at 5 months after treatment, 38% of patients had visible results with Jeuveau® **
* 54% of patients had a >1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint). In US studies, 46% and 56% had a >1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.
** 38% of patients had a >1-grade improvement in frown lines at 5 months based on physician assessment compared to 8% for placebo (secondary endpoint). In US studies, almost 5% of patients had a >2-grade improvement in frown lines at 5 months based on both patient and physician assessments compared to 0% for placebo (secondary endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.
What's it like before and after treatment?
If it’s your first time getting a treatment, you may be a little nervous and that’s okay! Localized pain, infection, inflammation, tenderness, swelling, erythema, and/or bleeding/bruising may be associated with the injection.
For specific instructions on what to do before and after your injection, please follow the instructions as given to you by your doctor or healthcare provider.
What are the side effects?
The most common side effects of Jeuveau® include: headache, eyelid dropping, upper respiratory infection, and increased white blood cell count. These are not all the possible side effects of Jeuveau®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. No serious drug-related adverse events were observed in the studies.